Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease

OBJECTIVE:To evaluate the adenosine 2a receptor antagonist preladenant as a nondopaminergic drug for the treatment of Parkinson disease (PD) when given as monotherapy. METHODS:This was a randomized, 26-week, placebo- and active-controlled, parallel-group, multicenter, double-blind trial conducted in...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Neurology 2017-06, Vol.88 (23), p.2198-2206
Hauptverfasser:	Stocchi, Fabrizio, Rascol, Olivier, Hauser, Robert A, Huyck, Susan, Tzontcheva, Anjela, Capece, Rachel, Ho, Tony W, Sklar, Peter, Lines, Christopher, Michelson, David, Hewitt, David J
Format:	Artikel
Sprache:	eng
Schlagworte:	Activities of Daily Living Adenosine A2 Receptor Antagonists - therapeutic use Antiparkinson Agents - adverse effects Antiparkinson Agents - therapeutic use Dose-Response Relationship, Drug Double-Blind Method Female Humans Indans - adverse effects Indans - therapeutic use Internationality Male Middle Aged Motor Activity - drug effects Parkinson Disease - drug therapy Pyrimidines - adverse effects Pyrimidines - therapeutic use Severity of Illness Index Treatment Failure Triazoles - adverse effects Triazoles - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	OBJECTIVE:To evaluate the adenosine 2a receptor antagonist preladenant as a nondopaminergic drug for the treatment of Parkinson disease (PD) when given as monotherapy. METHODS:This was a randomized, 26-week, placebo- and active-controlled, parallel-group, multicenter, double-blind trial conducted in adults diagnosed with PD for
ISSN:	0028-3878 1526-632X
DOI:	10.1212/WNL.0000000000004003